Preliminary List of Invited Presentations
As at 1 February, 2017

**Basic Research, Molecular Biology**

Chronic Ischemia: Time to Review all the Concepts?
**Roberto Ferrari,** Universita Di Ferrara, Divisione Di Cardiologia, Ferrara, Italy

Sex Differences in Cardiac Tolerance to Oxygen Deprivation: The Role of Mitochondria
**Bohuslav Ostadal,** Academy of Sciences of the Czech Republic, Prague, Czech Republic

Regulation of Mitochondria and Cell Death Signaling Pathways in the Heart
**Lorrie A. Kirshenbaum,** St. Boniface Hospital Research, Winnipeg, Manitoba, Canada

Molecular Imaging of Atherothrombotic Disease: Future Opportunities for Various Imaging Modalities
**Karlheinz Peter,** Baker IDI Heart & Diabetes Institute, Melbourne, VC, Australia

Vasoprotective Actions of the Novel Redox Signaling Molecule, Nitroxyl (HNO)
**Barbara K. Kemp-Harper,** Monash University, Clayton VIC, Australia

Cytokines and Oxidative Stress in Heart Failure
**Pawan K. Singal,** St. Boniface Hospital Research, Winnipeg, Manitoba, Canada

Mechanism Based Therapeutic Strategies to Target Mitochondrial Stress and Endoplasmic Reticulum Stress in Rodent Stroke Models
**Howard Prentice,** Florida Atlantic University, Boca Raton, FL, USA

Role of Reactive Oxygen Species in Adenosine-Mediated Regulation of Coronary Flow
**S. Jamal Mustafa,** School of Medicine, West Virginia University, Morgantown, WV, USA

Abnormalities of Cardiolipin Synthesis and Remodeling in Heart Failure: A Cornerstone of Energy Deprivation
**Hani Sabbah,** Henry Ford Heart and Vascular Institute, Detroit, MI, USA

Sudden Cardiac Death Substrates and Triggers: Ischemia and Potassium
**Keld Kjeldsen,** Copenhagen University Hospitals, Copenhagen and Holbæk, and The Faculty of Medicine, Aalborg University, Aalborg, Denmark

Cardiogenesis and Reversal of Stem Cell Aging by Asymmetrically Conveyed Electromagnetic Fields
**Carlo Ventura,** University of Bologna, Bologna, Italy

The Evolving Understanding of Atherosclerosis
**Michael Simons,** Yale University School of Medicine, New Haven, CT, USA

**Acute Coronary Syndromes, Acute Myocardial Infarction**

Update on the 4th Revision of the Universal Definition of MI with Particular Emphasis on Non-Ischemic Myocardial Injury
**Joseph S. Alpert,** University of Arizona Health Sciences Center, Tucson, AZ, USA

Myocardial Infarction and Non-Obstructive Coronary Arteries (MINOCA)
**Stefan Agewall,** Oslo University Hospital Ullevål, University of Oslo, Oslo, Norway
Acute Coronary Syndromes, Insights from Intravascular Imaging
Robert L. Wilensky, Penn Cardiovascular Institute, Philadelphia, PA, USA

STEMI Systems of Care
Marco Tubaro, San Filippo Neri Hospital, Rome, Italy

STEMI in Hospitalized Patients: What can we do to Improve Outcomes?
George A. Stouffer, University of North Carolina, Chapel Hill, NC, USA

Targeting Cardiac Inflammation Post MI to Limit Cardiac Necrosis and Contractile Dysfunction
Rebecca Ritchie, Baker Institute, Melbourne, Australia

The Copernican Revolution in Ischemic Heart Disease
Mario Marzilli, University of Pisa, Pisa, Italy

Periprocedural Antithrombotic Medication in PCI for ACS
Petr Widimsky, Cardiocenter Vincheadt and Charles University, Praha, Czech Republic

New Challenges in Acute Coronary Syndrome Trials: The European Medicine Agency (EMA) Perspective
Angeles Alonso, European Medicines Agency’s Scientific Advice Working Party, Madrid, Spain

Novel Recombinant Biologics for the Treatment of Acute Coronary Syndromes and Infarction
Francis G. Spinale, University of South Carolina School of Medicine, Columbia, SC, USA

Ventricular Function, Heart Failure

Heart Rate Slowing for Relief of Heart Failure Due to Coronary Artery Disease
Jeffrey S. Borer, New York (SUNY) Downstate Medical Center and SUNY Downstate College of Medicine, New York, NY, USA

Contemporary Therapy in Congestive Heart Failure
Prakash C. Deedwania, VA Medical Center, Fresno, CA, USA

Novel Pharmaceutical Concepts in Cardiac Remodeling
Dennis V. Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece

Cardiac Wound Healing and Heart Failure
Georg Ertl, University Hospital Würzburg, Würzburg, Germany

Nepirilysn Inhibition in Ischemic Heart Disease with Heart Failure: Current Update
Uday Jadhav, Dept. of Cardiology, MGM New Bombay Hospital, Vashi, India

The Treatment of the Diabetic Patient with Heart Failure
Giuseppe Rosano, St George’s University of London, London, UK

Depression and Anxiety in Heart Failure
Christiane Angermann, University Hospital Würzburg, Würzburg, Germany

Coronary Revascularization in Patients with Heart Failure: State-of-the-Art 2017
Petar Seferovic, Heart Failure Center, University of Belgrade School of Medicine, Belgrade, Serbia
**Antithrombotic Therapy**

Clinical Relevance of Immature Reticulated Platelets in Patients with Coronary Artery Disease
**Eli Lev**, Rabin Medical Center and Tel Aviv University, Tel Aviv, Israel

Antithrombotic Therapy in Patients with AF and ACS
**Cetin Erol**, Ankara University Faculty of Medicine, Ankara, Turkey

Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing PCI with Stent
**Giuseppe Di Pasquale**, Ospedale Maggiore, Bologna, Italy

Use of Oral Anticoagulation in Patients Received Antiplatelet Agents
**Shinya Goto**, Tokai University, Kanagawa, Japan

Compliance, Thrombosis and Bleeding With NOACs: Experience From Real Life Data
**Christian Torp-Pedersen**, Aalborg University, Aalborg, Denmark

Left Atrial Appendage Closure - Alternative to Anticoagulation?
**Amir Halkin**, Tel Aviv Medical Center and Tel Aviv University, Tel Aviv, Israel

**Pharmacotherapy**

Drugs for Cardiac Protection
**Qin M. Chen**, University of Arizona, Tucson, AZ, USA

Advances in the Management of Patients with Stable Angina and Type 2 Diabetes
**Juan Tamargo**, Universidad Complutense de Madrid, Madrid, Spain

Management of Stable Angina 2017: A Critical Appraisal
**Udho Thadani**, University of Oklahoma, Oklahoma City, OK, USA

Clinical Approach To Anti-Thrombotic Pre-Treatment For Patients With Acute Coronary Syndromes (ACS)
**Roberto Caporale**, Ospedale Civile dell’Annunziata, Cosenza, Italy

**Lipidology, Diabetes, Risk Factors**

Is an Even Lower LDL-C Better - and Safe?
**Evan A. Stein**, Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA

The New Lipidology and Prevention of Vascular Dusease - Lessons from FOURIER and other lipid lowering trials
**Robert P. Giugliano**, TIMI Study Group and Harvard Medical School, Boston, MA, USA

PCSK9 Inhibition: Learning From Nature
**Heinz Drexel**, Academic Teaching Hospital Feldkirch and VIVIT Institute, Feldkirch, Austria

Novel Lipid Modifying Therapies beyond Statins
**Prediman K. Shah**, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Polyphenols and Atherosclerosis
**Paul G. Hugenholtz**, Erasmus University, Rotterdam, The Netherlands
European Consensus for Atherogenic Dyslipidaemia Management

Jesus M. Núñez-Cortés, Facultad de Medicina de la Universidad Complutense, Spain

Lipid Lowering and Blood Pressure Lowering as Primary Prevention: What have we Learnt from HOPE-3?

Basil S. Lewis, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Haifa, Israel

Novel Antidiabetes Drugs With Cardiovascular Benefit – Is There Reason for Enthusiasm?

Thomas A Schmidt, Holbaek University Hospital, University of Copenhagen, Copenhagen, Denmark

Dapagliflozin, a SGLT-2 Inhibitor, has a Direct Effect on Cardiofibroblasts, Attenuating Inflammation and Progression of Diabetic Cardiomyopathy

Yochai Birnbaum, Baylor College of Medicine, Houston, TX, USA

Novel Anti-Diabetic Therapies and Cardio-Metabolic Control

Manfredi Rizzo, University of Palermo, Palermo, Italy

SGLT2 Inhibitors: The Cardiologist’s Point of View

Yoseph Rozenman, Wolfson Medical Center and Tel Aviv University, Holon, Israel

DPP-4 Inhibitors: Preservation of Endothelial Function in the Presence of Oxidative Stress

Owen L. Woodman, RMIT University, Bundoora Vic, Australia

Epidemiology and Prevention

SCORE Deutschland Update 2016

Ulrich Keil, University of Munster, Munster, Germany

Cardiac Risk in Primary Prevention: From Categorical to Individual Risk

Joseph Shemesh, Sheba Medical Center and Tel Aviv University, Tel Hashomer, Israel

Hypertension and Coronary Artery Disease

Management of Hypertension in Patients with CAD

Clive Rosendorff, Mount Sinai School of Medicine, New York, NY, USA

Exercise Related Hypertension may Not Be a Benign Phenomenon

Yzhar Charuzi, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Clinical Aspects

Microvascular Coronary Disease and Clinical Implications

Juan Carlos Kaski, Cardiovascular and Cell Sciences Research Institute, St George’s University of London, London, UK

Hematology as Predictor of Cardiovascular Outcome

Imo Hoefer, University Medical Center, Utrecht, The Netherlands

Tako-Tsubo Cardiomyopathy: Diagnosis, Pathogenesis and Treatment

John D. Horowitz, University of Adelaide, Adelaide, Australia
Aging and Obesity
Bohd I. Jugdutt, University of Alberta Hospitals, Edmonton, Alberta, Canada

Cardio-Oncology: What to Consider and What to Look For
Jutta Bergler-Klein, Medical University of Vienna, Vienna, Austria

Diagnosis and Imaging Techniques

Update on CCTA as a Tool for Cardiac Risk Reclassification
Andre Duerinckx, Howard University College of Medicine, Washington, DC, USA

Can we Predict Vulnerable Plaques by Non-Invasive Imaging Techniques?
David A. Halon, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Haifa, Israel

Functional Evaluation of CAD by CTA: CT-FFR, CT Perfusion, Transluminal Attemuation Gradient
Harvey Hecht, Icahn School of Medicine, Saint Luke’s Mount Sinai Medical Center, New York, NY, USA

Fusion Imaging in Cardiac Diagnosis
Ronen Rubinshtein, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Haifa, Israel

Diffusion Tensor Magnetic Resonance of Cardiac Microstructure and Application to Coronary Artery Disease
Dudley J. Pennell, NIHR Cardiovascular Biomedical Research Unit, National Heart and Lung Institute, Imperial College, London, UK

Cardiac PET-MRI: Our Experience
Jie Zheng, Mallinckrodt Institute of Radiology, Saint Louis, MO, USA

Speckle Tracking Echocardiography: Ready for Routine Clinical Use?
Zvi Vered, Assaf Harofeh Medical Ctr and Tel Aviv University, Zerifin, Israel

Interventional Cardiology

Angiography alone is Insufficient to Guide PCI: The Role of Direct Coronary Imaging
James A. Goldstein, William Beaumont Hospital, Royal Oak, MI, USA

Update on FFR 2017
Barry F. Uretsky, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Current Status of New Generation Drug Eluting Stents: The Ultimaster
Shigeru Saito, Shonan Kamakura General Hospital, Kamakura, Japan

Emerging Stent Technologies
Ian B.A. Menown, Irish Atherosclerosis Society and Craigavon Cardiac Center and Queens University, Belfast, Northern Ireland
BRS - a Real Breakthrough or Not?
**Chaim Lotan**, Hadassah Hospital and the Hebrew University, Jerusalem, Israel

European Stent for Life Initiative Achievements in STEMI
**Petr Kala**, University Hospital Brno, Brno, Czech Republic

Prognostic impact of anemia on cardiovascular outcome in patients undergoing PCI
**Sorin J. Brener**, Methodist Hospital and Weill Cornell Medical College, New York, NY, USA

Mechanisms of Stent Thrombosis Analysed by Optical Coherence Tomography: Insights from the National PESTO French Registry
**Géraud Souteyrand**, CHU Clermont-Ferrand, France

Vein Graft Intervention: Progress and Continued Challenges
**Michael Savage**, Thomas Jefferson University Hospital, Philadelphia, PA, USA

The future management of CAD – from diagnosis to treatment
**Giora Weisz**, Shaarei Zedek Medical Center and the Hebrew University, Jerusalem, Israel

**TAVI and Valvular Interventions**

TAVR 2017
**Haim Danenberg**, Hadassah Hospital and the Hebrew University, Jerusalem, Israel

TAVI and PCI: How should we Treat both AS and CAD?
**Ran Kornowski**, Rabin Medical Center and Tel Aviv University, Tel Aviv, Israel

Vascular Access for Transcatheter Aortic Valve Replacement: Challenges and Novel Approaches
**Ronen Jaffe**, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Haifa, Israel

TAVI: Are we Doing too Many Futile Cases?
**Amit Segev**, Sheba Medical Center and Tel Aviv University, Tel Hashomer, Israel

TAVI: the Minimalistic Approach
**Ariel Finkelstein**, Tel Aviv Medical Center and Tel Aviv University, Tel Aviv, Israel

3rd Generation TAVI Devices: Great Tools for Cardiac Surgeons and Cardiologists
**Hermann Reichenspurner**, Universitatsklinikum Eppendorf, Hamburg, Germany

Mini Invasive Suturless Aortic Valve Implantation Compared to TAVI in Intermediate Risk Patients
**Ehud Raanani**, Sheba Medical Center and Tel Aviv University, Tel Hashomer, Israel

Valve Prosthesis Patient Mismatch: Keep it Simple
**Shahbudin H. Rahimtoola**, University of Southern California School of Medicine, Los Angeles, CA, USA

**Carotid and Peripheral Interventions**

Managing the Asymptomatic Carotid Stenosis
**Bruce Gewertz**, Cedars-Sinai Medical Center, Los Angeles, CA, USA

The Fallacy of Preventive Surgery: The Case of Carotid Repair for the Primary Prevention of Stroke
Roberto Pedrinelli, University of Pisa, Pisa, Italy
Endovascular Metabolic Interventions - Next Revolution?
Nicholas Kipshidze, New York Cardiovascular Research, New York, NY, USA

Cardiac Surgery
Surgical Options for End-Stage Coronary Artery Disease
Roland Hetzer, German Heart Institute, Berlin, Germany
Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in Cardiac Surgery
Shuli Silberman, Shaarei Zedek Medical Center and the Hebrew University, Jerusalem, Israel
Small Calibre Tissue Engineered Vascular Grafts
Beat H. Walpoth, Geneva University Hospital, Geneva, Switzerland
Mitral Valve Repair - an Exclusive Echo Guided Approach
Alfredo Trento, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Current Status of Mitral Valve Repair Therapies
Matthias Overbeck, München, Germany
Ventricular Assist Devices or Total Artificial Heart for Advanced and End-stage Heart Failure
Marvin J. Slepian, Arizona Center for Accelerated Biomedical Innovation, University of Arizona, Tucson, AZ, USA

CLINICAL TRIALS WORKSHOP (ESC Working Group on Cardiovascular Pharmacotherapy)
Details TBA

SPECIAL JOINT SESSION with the Acute Cardiovascular Care Association (ACCA) of the ESC
Title: Inflammation and Atherothrombosis – New Clinical Aspects
The Year In ACS – Emerging Therapies in Atherothrombosis
Maddalena Lettino (Milano, Italy) – ACCA President
Anti-Inflammatory Therapies To Stop The Progression Of Atherosclerosis
Andreas Zirlik (Freiburg, Germany)
Targeting Cardiac Inflammation Post MI To Limit Cardiac Necrosis And Contractile Dysfunction
Rebecca Ritchie (Melbourne, Australia)
Update Antithrombotic Therapy in Patients Post TAVI
Ingo Ahrens (Cologne, Germany) – Co-Chair ACCA Scientific Committee
Inflammatory Response After Out-Of-Hospital Cardiac Arrest – A Potential Therapeutic Target?
Christian Hassager (Copenhagen, Denmark) – Chair ACCA Scientific Committee